Florida Cancer Specialists & Research Institute’s Post

3 year update for KN716 now online in Journal of Clinical Oncology. https://lnkd.in/eUum53Bx Foundational data for adjuvant #melanoma emphasizing patients with stage IIB/C disease are at high risk & pembrolizumab is highly effective to prevent recurrence. Next step - biomarker work to optimize patient selection!

What is the future of cancer treatment? Gretchen Knoll is the most recent guest on Trials with Maya Z. She has over 20 years of experience in pharmaceutical clinical development, now she focuses on enhancing care for severely ill patients and reducing healthcare costs through strategic collaborations. Maya and Gretchen Knoll discuss the challenges and potential transformations in #clinicalresearch. They delve into the need for a shift from organ-based #cancertreatment to #tumorclassification and much more. - Why do we need to shift from organ to receptor-based classification - The challenges with using molecular testing at scale - What are the challenges and opportunities in clinical trials - What is the new role of psychedelics in clinical research - The power of predictive analytics and AI in medicine - How to empower patients for better trial outcomes Tune in today for expert insights into the world of clinical research. #clinicaltrials #oncology #cancertreatment

We’re excited to share today updated preliminary clinical data from the Phase 1 portion of our ongoing StrateGIST 1 study of IDRX-42 in patients with advanced gastrointestinal stromal tumors, or #GIST, at the American Society of Clinical Oncology (ASCO)’s Annual Meeting. Encouraging signs of clinical activity were observed, including a 23% objective response rate across all patients in a heavily pretreated patient population, and a 43% objective response rate across second-line patients. A favorable tolerability profile was also observed. “In this dataset, IDRx has presented preliminary proof-of-concept of IDRX-42 supporting its potentially best-in-class profile in patients with GIST,” said Tim Clackson, Ph.D., Chief Executive Officer of IDRx. “Importantly, we believe these efficacy and safety data support our plan to move IDRX-42 rapidly into early lines of therapy, including second-line and front-line, where patients haven’t seen a new treatment option in over 15 years.” Read more: https://lnkd.in/ePCh693j Discover more during our oral presentation at #ASCO24: https://lnkd.in/eiPSyZ9f

Latest and promising data for IDRX-42 in GIST, just presented at the American Society of Clinical Oncology (ASCO) 2024 meeting. #sarcoma #GIST #ASCO2024

Discover the benefits of bi-specific antibodies in Multiple Myeloma treatment with leading oncology experts Ryan Haumschild PharmD, MS, MBA, CPEL; Matt Pianko MD; and Anthony Perissinotti, PharmD, BCOP. Explore the efficacy and safety of these novel treatments while uncovering practical considerations such as patient selection, treatment logistics, unmet educational needs, and more! Access the trending Practice Pearls episodes here: https://bit.ly/3HwOW8U

Join Nataliya Mar, MD and the Medical Oncology Association of Southern California, Inc. for a #genitourinarycancer webinar focusing on #urothelialbladdercancer on Thursday, Feb. 1, 2024, from 5:30-6:30 p.m. PT. As moderator, Mar will dive into the latest updates in clinical practice, research & development, and technology & drug advancements in the treatment of genitourinary cancers. The panelists will spotlight adjuvant therapy selection for high-risk muscle-invasive patients post cystectomy/nephroureterectomy and front-line therapy selection for locally advanced/metastatic disease. This virtual learning symposium will offer an interactive format, the professional exchange of ideas, and a discussion of trials that may improve patient outcomes. Register: https://lnkd.in/gehFK_HE #GenitourinaryCancer #UrothelialBladderCancer #MedicalEducation #ClinicalUpdates #CancerResearch

It's HERE! Clarivate 's annual Drugs to Watch report, identifying the potential blockbuster drugs that are poised to have a transformational impact on patient outcomes! Everything you need to know is directly below:

#ThinkForward #DrugstoWatch #Healthcare The 11th annual Drugs to Watch Report just released by Clarivate. Link below to learn more

Who am I gonna see in Vegas next week?🙌 Speaking of precision medicine 👉 did you see inavolisib (Itovebi - where do they come up w/ these names 🤷♀️) just got FDA approved in combo w/ Ibrance & Fulvestrant for endocrine-resistant, PIK3CAm/HR+/HER2- metastatic breast cancer after prior adjuvant endocrine tx‼️ Was waiting for thisl! It’s a big one in the metastatic breast cancer space. 1st triplet front-line endocrine-based therapy for a very select population. 57%⬇️ in risk of disease progression or death w/ adding inavolisib to Ibrance/Fulvestrant! Curious what the cost will be though (let me know if you see it)!💸 On the theme of biomarker testing… we need to ensure PIK3CA is tested front-line in HR+ MBC now vs 2nd line or later to identify those that would could benefit! Leave no patient behind! FoundationOne Liquid NGS is called out as the companion diagnostic. Who else is excited about this!?! (Yes , I know I’m weird, it’s breast cancer people—you know that’s my jam!)👩🔬 https://lnkd.in/e7SjQTAY

In the field of oncology, subcutaneous administration faces several common hurdles. These include significant transformations of patient pathway, need for effective training solutions, building of self-management support, and ability to collect and analyze meaningful data. Remote monitoring and self-management support are just a few patient-centric solutions features addressing these types of challenges. Aptar Digital Health and Gerresheimer have recently published an article on this topic in On Drug Delivery. Learn more by below